Biotechnology pioneer discovering, developing, manufacturing, and delivering human therapeutics for serious illnesses.
Profile & Fundamentals
Review the profile, reported financial history, AI financial assessment, dividends, splits, and dated events for Amgen.
Profile & Fundamentals
Amgen Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he
Company profile record
Amgen Inc
Common Stock · Healthcare · Drug Manufacturers - General
Company
- Company / asset
- Amgen Inc
- Security type
- Common Stock
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- HQ
- 🇺🇸 United States
- Head office
- One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799
Leadership & scale
- Chief executive
- Mr. Robert A. Bradway
- CEO year born
- 1963
- Full-time employees
- 31.5K
- Fiscal year end
- December
- IPO date
- 1983-06-17
Fundamentals snapshot
- Market Cap
- USD 209.5B
- P/E
- 26.9x
- Revenue (Q1 26)
- USD 8.6B
- Profit (Q1 26)
- USD 1.8B
- Dividend Yield
- 1.8%
- Revenue (FY 25)
- USD 36.7B
- Shares in public float
- 538.2M
- Insider ownership
- 0.22%
Reporting & identifiers
- Symbol
- AMGN.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US0311621009
- Asset ID
- equity_3f8ad8b5-f4b0-5cb9-9c03-b91a45b1c70a
Ownership
Shares Outstanding
Latest: 544.0M | Max: 1.1B | Min: 539.0M
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open every chart, financial statement, event, and source table.